Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a


Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului



Yüklə 4,39 Mb.
səhifə362/381
tarix07.01.2022
ölçüsü4,39 Mb.
#80899
1   ...   358   359   360   361   362   363   364   365   ...   381
Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L04AA10 SIROLIMUS COMPR. FILM. 1 mg

RAPAMUNE 1 mg 1 mg WYETH EUROPA LTD.

________________________________________________________________________________


______________________________________________________________________________

| 989 |L04AX01| AZATHIOPRINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L04AX01 AZATHIOPRINUM COMPR. FILM. 50 mg

IMURAN(R) 50 mg THE WELLCOME FOUNDATION

LTD.


________________________________________________________________________________
______________________________________________________________________________

| 990 |M05BA04| ACIDUM ALENDRONICUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

M05BA04 ACIDUM ALENDRONICUM COMPR. 10 mg

FOSAMAX 10 mg 10 mg MERCK SHARP & DOHME S.R.L.
M05BA04 ACIDUM ALENDRONICUM COMPR. 70 mg

TEVA NAT 70 mg TEVA PHARMACEUTICALS SRL


M05BA04 ACIDUM ALENDRONICUM COMPR. 70 mg

FOSAMAX 70 mg 70 mg MERCK SHARP & DOHME S.R.L.

________________________________________________________________________________
______________________________________________________________________________

| 991 |N02AB02| PETHIDINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

N02AB02 PETHIDINUM SOL. INJ. 50 mg/ml

MIALGIN(R) 100 mg/2 ml 50 mg/ml ZENTIVA SA

________________________________________________________________________________


______________________________________________________________________________

| 993 |B01AB08| REVIPARINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

B01AB08 REVIPARINUM SOL. INJ.

CLIVARIN (R) 1432 UI/0.25 ml 1432 ui/0.25 ml ABBOTT GMBH & CO. KG

CLIVARIN(R) 1432 UI/0.25 ml 1432 ui/0.25 ml ABBOTT GMBH & CO. KG


B01AB08 REVIPARINUM SOL. INJ.

CLIVARIN (R) 3436 UI/0,6 ml 3436 ui/0.6 ml ABBOTT GMBH & CO. KG

CLIVARIN(R) 3436 UI/0,6 ml 3436 ui/0.6 ml ABBOTT GMBH & CO. KG

________________________________________________________________________________


______________________________________________________________________________

| 994 |B05AA06| POLYGELINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

B05AA06 POLYGELINUM SOL. PERF. 3.5%

HAEMACCEL 3.5% THERASELECT GMBH

________________________________________________________________________________


______________________________________________________________________________

| 995 |J01XX08| LINEZOLIDUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01XX08 LINEZOLIDUM GRAN. PT. SUSP. ORALA

ZYVOXID(R) 100 mg/5 ml PFIZER EUROPE MA EEI

ZYVOXID(R) 100 mg/5 ml PFIZER EUROPE MA EEIG


J01XX08 LINEZOLIDUM SOL. PERF.

ZYVOXID(R) 2 mg/ml PFIZER EUROPE MA EEI

ZYVOXID(R) 2 mg/ml PFIZER EUROPE MA EEIG
J01XX08 LINEZOLIDUM COMPR. FILM.

ZYVOXID(R) 600 mg PFIZER EUROPE MA EEI

ZYVOXID(R) 600 mg PFIZER EUROPE MA EEIG

________________________________________________________________________________


______________________________________________________________________________

| 996 |J02AC03| VORICONAZOLUM** | Protocol: J012B |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J02AC03 VORICONAZOLUM COMPR. FILM.

VFEND(R) 200 mg PFIZER LIMITED

VFEND 200 mg 200 mg PFIZER LTD.


J02AC03 VORICONAZOLUM PULB. PT. SOL. PERF.

VFEND(R) 200 mg PFIZER LIMITED

VFEND 200 mg 200 mg PFIZER LTD.
J02AC03 VORICONAZOLUM PULB. PT. SUSP. ORALA

VFEND(R) 40 mg/ml 40 mg/ml PFIZER LIMITED

VFEND 40 mg/ml 40 mg/ml PFIZER LTD.
J02AC03 VORICONAZOLUM COMPR. FILM.

VFEND(R) 50 mg PFIZER LIMITED

VFEND 50 mg 50 mg PFIZER LTD.

________________________________________________________________________________


______________________________________________________________________________

| 998 |J05AB14| VALGANCICLOVIRUM** | |

|_______|_______|____________________________________________|_________________|
Prescriere limitată: Tratamentul de iniţiere şi menţinere pentru retinita cu citomegalovirus (CMV) la pacienţi imunocompromişi.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J05AB14 VALGANCICLOVIRUM COMPR. FILM. 450 mg

VALCYTE(R) 450 mg 450 mg ROCHE ROMANIA SRL
J05AB14 VALGANCICLOVIRUM COMPR. FILM.

VALCYTE(R) 450 mg 450 mg ROCHE ROMANIA SRL

________________________________________________________________________________
SUBLISTA C2-P9: PROGRAM NAŢIONAL DE TRANSPLANT DE ORGANE, ŢESUTURI ŞI CELULE DE ORIGINE UMANĂ. P9.6 TRANSPLANT PULMONAR
______________________________________________________________________________

| 999 |B01AB05| ENOXAPARINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

B01AB05 ENOXAPARINUM SOL. INJ. 2000 ui

anti-Xa/0.2 ml

CLEXANE 2000 ui 2000 ui anti-Xa/0.2 ml LAB. AVENTIS

anti-Xa/0.2 ml
B01AB05 ENOXAPARINUM SOL. INJ. 4000 ui

anti-Xa/0,4ml

CLEXANE 4000 ui 4000 ui anti-Xa/0,4 ml LAB. AVENTIS

anti-Xa/0.4 ml


B01AB05 ENOXAPARINUM SOL. INJ. 6000 ui

anti-Xa/0.6 ml

CLEXANE 6000 ui 6000 ui anti-Xa/0.6 ml LAB. AVENTIS

anti-Xa/0.6 ml


B01AB05 ENOXAPARINUM SOL. INJ. 8000 ui

anti-Xa/0.8 ml

CLEXANE 8000 ui 8000 ui anti-Xa/0.8 ml LAB. AVENTIS

anti-Xa/0.8 ml


B01AB05 ENOXAPARINUM SOL. INJ. 2000 ui

anti-Xa/0.2 ml

CLEXANE 2000 ui 2000 ui anti-Xa/0.2 ml LAB. AVENTIS

anti-Xa/0.2 ml


B01AB05 ENOXAPARINUM SOL. INJ. 4000 ui

anti-Xa/0,4 ml

CLEXANE 4000 ui 4000 ui anti-Xa/0,4 ml LAB. AVENTIS

anti-Xa/0.4 ml


B01AB05 ENOXAPARINUM SOL. INJ. 6000 ui

anti-Xa/0.6 ml

CLEXANE 6000 ui 6000 ui anti-Xa/0.6 ml LAB. AVENTIS

anti-Xa/0.6 ml

________________________________________________________________________________
______________________________________________________________________________

| 1000 |B01AB08| REVIPARINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

B01AB08 REVIPARINUM SOL. INJ. 1432 ui/0.25 ml

CLIVARIN(R) 1432 UI/0.25 ml 1432 ui/0.25 ml ABBOTT GMBH & CO. KG
B01AB08 REVIPARINUM SOL. INJ. 3436 ui/0.6 ml

CLIVARIN(R) 3436 UI/0,6 ml 3436 ui/0.6 ml ABBOTT GMBH & CO. KG

________________________________________________________________________________
______________________________________________________________________________

| 1002 |C01CA24| EPINEPHRINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

C01CA24 EPINEPHRINUM SOL. INJ. 1 mg/ml

ADRENALINA 1 mg 1 mg/ml TERAPIA SA

________________________________________________________________________________


______________________________________________________________________________

| 1003 |J01CR05| PIPERACILLINUM + TAZOBACTAMUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01CR05 PIPERACILLINUM + LIOF. PT. SOL. INJ.

TAZOBACTAMUM

TAZOCIN 2,25 WYETH LEDERLE PHARMA GMBH

TAZOCIN 4,5 WYETH LEDERLE PHARMA GMBH

________________________________________________________________________________


______________________________________________________________________________

| 1004 |J01XX08| LINEZOLIDUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01XX08 LINEZOLIDUM GRAN. PT. SUSP. ORALA 100 mg/5 ml

ZYVOXID(R) 100 mg/5 ml PFIZER EUROPE MA EEIG
J01XX08 LINEZOLIDUM SOL. PERF. 2 mg/ml

ZYVOXID(R) 2 mg/ml PFIZER EUROPE MA EEIG


J01XX08 LINEZOLIDUM COMPR. FILM. 600 mg

ZYVOXID(R) 600 mg PFIZER EUROPE MA EEIG

________________________________________________________________________________
______________________________________________________________________________

| 1005 |J02AC01| FLUCONAZOLUM | |

|_______|_______|____________________________________________|_________________|
Prescriere limitată: Tratament de întreţinere la pacienţi cu meningită


Yüklə 4,39 Mb.

Dostları ilə paylaş:
1   ...   358   359   360   361   362   363   364   365   ...   381




Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©muhaz.org 2024
rəhbərliyinə müraciət

gir | qeydiyyatdan keç
    Ana səhifə


yükləyin